MAPT and chronic myelogenous leukemia, BCR-ABL1 positive: The FDA-approved compound dasatinib, for the treatment of chronic myeloid leukemia, and one of the top up-regulators identified in our search, has reduced tau pathology in mice (Roberts et al., 2021) and is the subject of an ongoing clinical study evaluating its feasibility and efficacy modulating AD’s progression in combination with the naturally derived anti-inflammatory quercetin (Advani and Kumar, 2021; Gonzales et al., 2022).